Patient Characteristics
| Characteristic | Data (n = 145) |
| Median age (y) | 56 (range, 16–84) |
| Sex (n) | |
| Male | 67 (46%) |
| Female | 78 (54%) |
| Histologic subtype (n) | |
| DLBCL | 139 (96%) |
| PMBCL | 6 (4%) |
| Stage (n) | |
| I | 13 (9%) |
| II | 43 (30%) |
| III | 28 (19%) |
| IV | 61 (42%) |
| Performance status: ECOG ≥ 2 (n) | 23 (16%) |
| Number of extranodal manifestations ≥ 2 (n) | 40 (28%) |
| Elevated LDH level (n) | 71 (48.9%) |
| Bulky tumor* (n) | |
| Bulky | 43 (30%) |
| Very extensive disease | 32 (22%) |
| aaIPI risk (n) | |
| Low | 38 (26%) |
| Low-intermediate | 49 (34%) |
| High-intermediate | 40 (28%) |
| High | 18 (12%) |
| Prognosis according to R-IPI (n) | |
| Very good (IPI, 0) | 24 (16%) |
| Good (IPI, 1–2) | 75 (52%) |
| Poor (IPI, 3–5) | 46 (32%) |
| Immunochemotherapy† (n) | |
| R-CHOP-21, 4–8 cycles | 117 (81%) |
| R-CHOP-14, 4–8 cycles | 23 (16%) |
| R-CEOP-21, 4–8 cycles | 5 (3%) |
| Consolidation IFRT | 47 (32%) |
↵* Bulky tumor: diameter > 5 cm; very extensive disease: diameter > 10 cm or at least 2 lesions with diameter > 7 cm.
↵† Planned number of cycles was defined according to local preferences: in stages I–II, minimally 4 cycles; in stages III–IV, 6–8 cycles.
PMBCL = primary mediastinal large B-cell lymphoma; ECOG = Eastern Cooperative Oncology Group; LDH = lactate-dehydrogenase; IPI = international prognostic index; aaIPI = age-adjusted IPI; R-IPI = revised IPI; R-CHOP-21 = rituximab, cyclophosphamide, doxorubicine, vincristine, prednisolone at 3-wk intervals; R-CHOP-14 = R-CHOP at 2-wk intervals; R-CEOP-21 = like R-CHOP-21, epirubicine instead of doxorubicin; IFRT = involved-field radiation therapy.